MediWound Ltd. (NASDAQ:MDWD) Stock Position Boosted by Yelin Lapidot Holdings Management Ltd.

Yelin Lapidot Holdings Management Ltd. grew its stake in shares of MediWound Ltd. (NASDAQ:MDWD) by 13.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 851,361 shares of the biopharmaceutical company’s stock after buying an additional 100,618 shares during the quarter. MediWound comprises 2.6% of Yelin Lapidot Holdings Management Ltd.’s holdings, making the stock its 12th biggest position. Yelin Lapidot Holdings Management Ltd. owned about 7.89% of MediWound worth $15,154,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in MDWD. Rhumbline Advisers lifted its holdings in shares of MediWound by 7.3% in the fourth quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company’s stock valued at $193,000 after buying an additional 739 shares during the period. Legato Capital Management LLC boosted its position in shares of MediWound by 12.0% during the 4th quarter. Legato Capital Management LLC now owns 43,753 shares of the biopharmaceutical company’s stock valued at $779,000 after purchasing an additional 4,681 shares in the last quarter. Sargent Investment Group LLC grew its stake in shares of MediWound by 3.4% in the 4th quarter. Sargent Investment Group LLC now owns 121,190 shares of the biopharmaceutical company’s stock worth $2,217,000 after purchasing an additional 3,998 shares during the last quarter. R Squared Ltd bought a new stake in shares of MediWound in the 4th quarter worth approximately $32,000. Finally, Silverberg Bernstein Capital Management LLC lifted its stake in MediWound by 8.5% during the fourth quarter. Silverberg Bernstein Capital Management LLC now owns 91,884 shares of the biopharmaceutical company’s stock valued at $1,636,000 after purchasing an additional 7,200 shares during the last quarter. 46.83% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of MediWound in a report on Friday, January 10th.

MediWound Trading Up 1.6 %

Shares of MDWD opened at $16.23 on Friday. MediWound Ltd. has a 1-year low of $12.78 and a 1-year high of $24.00. The stock has a market capitalization of $175.06 million, a P/E ratio of -5.60 and a beta of 0.81. The business’s 50-day moving average price is $18.18 and its 200 day moving average price is $17.72.

MediWound (NASDAQ:MDWD) last released its quarterly earnings results on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.50). MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same quarter last year, the business posted ($0.24) EPS. On average, research analysts predict that MediWound Ltd. will post -2.66 earnings per share for the current year.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.